New Antibiotics Celebrated as a 'Major Shift' in Combating Antibiotic-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the fight against drug-resistant strains of the infection, according to scientists.
A Worldwide Health Concern
Gonorrhoea infections are escalating globally, with data suggesting more than 82 million instances per year. Particularly high rates are reported in Africa and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.
“The authorization of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the very limited treatment choices presently on offer.”
Health officials are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.
Two New Therapies Secure Clearance
One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the emergence of superbugs.
Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.
A Unique Development Model
This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.
“This milestone signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”
Testing Data and Global Access
According to data released by a major medical journal, the new drug cured over nine in ten of cases of the STI. This establishes an similar efficacy with the typical regimen, which combines an injection and a pill. The trial enrolled hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its unique model, GARDP has the authority to make available and distribute the drug in many low-income and middle-income countries.
Clinicians directly involved have shared positive views. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for gonorrhoea control. This is viewed as vital to reduce the burden of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.
